Insider Selling: Cytokinetics, Incorporated (NASDAQ:CYTK) EVP Sells 2,000 Shares of Stock

Cytokinetics, Incorporated (NASDAQ:CYTK - Get Free Report) EVP Fady Ibraham Malik sold 2,000 shares of Cytokinetics stock in a transaction dated Tuesday, April 22nd. The stock was sold at an average price of $38.11, for a total value of $76,220.00. Following the completion of the transaction, the executive vice president now owns 140,255 shares in the company, valued at approximately $5,345,118.05. This represents a 1.41 % decrease in their position. The transaction was disclosed in a document filed with the SEC, which is available at this link.

Fady Ibraham Malik also recently made the following trade(s):

• On Tuesday, February 18th, Fady Ibraham Malik sold 2,000 shares of Cytokinetics stock. The shares were sold at an average price of $45.98, for a total transaction of $91,960.00.
• On Tuesday, February 4th, Fady Ibraham Malik sold 2,000 shares of Cytokinetics stock. The shares were sold at an average price of $48.06, for a total transaction of $96,120.00.

Cytokinetics Stock Up 0.2 %

NASDAQ CYTK traded up $0.10 during mid-day trading on Friday, reaching $40.43. The stock had a trading volume of 893,391 shares, compared to its average volume of 1,608,432. The company has a fifty day moving average price of $42.09 and a 200 day moving average price of $47.20. The company has a debt-to-equity ratio of 5.93, a current ratio of 9.28 and a quick ratio of 9.28. Cytokinetics, Incorporated has a 1 year low of $32.74 and a 1 year high of $68.44. The stock has a market cap of $4.82 billion, a PE ratio of -7.51 and a beta of 0.94.

Cytokinetics (NASDAQ:CYTK - Get Free Report) last announced its quarterly earnings results on Thursday, February 27th. The biopharmaceutical company reported ($1.26) earnings per share (EPS) for the quarter, beating analysts' consensus estimates of ($1.29) by $0.03. The business had revenue of $16.93 million for the quarter, compared to the consensus estimate of $14.26 million. On average, research analysts expect that Cytokinetics, Incorporated will post -5.24 earnings per share for the current year.

Institutional Trading of Cytokinetics

A number of large investors have recently made changes to their positions in CYTK. Jones Financial Companies Lllp increased its position in shares of Cytokinetics by 189.8% during the 4th quarter. Jones Financial Companies Lllp now owns 571 shares of the biopharmaceutical company's stock valued at $27,000 after purchasing an additional 374 shares during the last quarter. Centricity Wealth Management LLC purchased a new stake in shares of Cytokinetics in the 4th quarter worth $29,000. Fifth Third Bancorp raised its holdings in Cytokinetics by 42.2% in the 1st quarter. Fifth Third Bancorp now owns 981 shares of the biopharmaceutical company's stock worth $39,000 after purchasing an additional 291 shares during the period. Parallel Advisors LLC lifted its position in Cytokinetics by 500.5% during the first quarter. Parallel Advisors LLC now owns 1,099 shares of the biopharmaceutical company's stock valued at $44,000 after purchasing an additional 916 shares in the last quarter. Finally, GAMMA Investing LLC increased its position in Cytokinetics by 281.0% in the first quarter. GAMMA Investing LLC now owns 1,120 shares of the biopharmaceutical company's stock worth $45,000 after buying an additional 826 shares in the last quarter.

Analysts Set New Price Targets

A number of research analysts have commented on CYTK shares. Morgan Stanley set a $67.00 price target on Cytokinetics in a research report on Friday, March 7th. HC Wainwright reiterated a "buy" rating and issued a $120.00 price target on shares of Cytokinetics in a report on Monday, April 21st. JMP Securities restated a "market outperform" rating and issued a $78.00 price objective on shares of Cytokinetics in a report on Thursday, April 10th. Evercore ISI upgraded shares of Cytokinetics to a "strong-buy" rating in a research report on Friday, February 7th. Finally, Bank of America lowered their price objective on shares of Cytokinetics from $62.00 to $54.00 and set a "neutral" rating for the company in a report on Tuesday, April 15th. Two research analysts have rated the stock with a hold rating, fifteen have issued a buy rating and one has assigned a strong buy rating to the stock. According to MarketBeat.com, the company presently has a consensus rating of "Moderate Buy" and an average price target of $79.13.

Cytokinetics Company Profile

Cytokinetics, Incorporated, a late-stage biopharmaceutical company, focuses on discovering, developing, and commercializing muscle activators and inhibitors as potential treatments for debilitating diseases. The company develops small molecule drug candidates primarily engineered to impact muscle function and contractility.